Patents by Inventor Jimmy Andrew Rotolo
Jimmy Andrew Rotolo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11878047Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: GrantFiled: January 3, 2019Date of Patent: January 23, 2024Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Publication number: 20230218717Abstract: Provided are methods of administering a peptide antagonist of CCAAT/enhancer-binding protein beta (C/EBP?) and methods of treating solid tumors by administering a peptide antagonist of C/EBP?.Type: ApplicationFiled: June 21, 2021Publication date: July 13, 2023Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo, Alice Susannah Bexon, Robert E. Michel
-
Publication number: 20220354861Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: ApplicationFiled: November 30, 2021Publication date: November 10, 2022Inventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK, Renata PASQUALINI, Wadih ARAP
-
Publication number: 20220275036Abstract: Provided are BCL9 mimetic peptides having a modified a-helical homology domain-2 (HD2) region and, optionally, a cell-penetrating region, compositions comprising the BCL9 mimetic peptides, and methods of inhibiting proliferation of and/or promoting cytotoxicity in a neoplastic cell using the BCL9 mimetic peptides.Type: ApplicationFiled: July 6, 2020Publication date: September 1, 2022Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo, Erin E. Gallagher
-
Publication number: 20220118087Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.Type: ApplicationFiled: July 17, 2020Publication date: April 21, 2022Inventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK
-
Patent number: 11207329Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: GrantFiled: February 27, 2018Date of Patent: December 28, 2021Assignees: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
-
Publication number: 20210061869Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: ApplicationFiled: January 3, 2019Publication date: March 4, 2021Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Patent number: 10722577Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.Type: GrantFiled: May 28, 2013Date of Patent: July 28, 2020Assignee: Sloan Kettering Institute for Cancer ResearchInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
-
Patent number: 10525100Abstract: Provided are activating transcription factor 5 (ATF5) peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: GrantFiled: January 3, 2019Date of Patent: January 7, 2020Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Publication number: 20190201483Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: ApplicationFiled: January 3, 2019Publication date: July 4, 2019Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Patent number: 10316077Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.Type: GrantFiled: February 17, 2018Date of Patent: June 11, 2019Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
-
Publication number: 20190046538Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: ApplicationFiled: February 27, 2018Publication date: February 14, 2019Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas SystemInventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK, Renata PASQUALINI, Wadih ARAP
-
Publication number: 20180237499Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.Type: ApplicationFiled: February 17, 2018Publication date: August 23, 2018Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
-
Publication number: 20170273987Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: ApplicationFiled: February 20, 2017Publication date: September 28, 2017Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas SystemInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
-
Patent number: 9592238Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: GrantFiled: August 23, 2013Date of Patent: March 14, 2017Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
-
Publication number: 20150216971Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, CGvHD disease, inflammatory diseases and autoimmune diseases.Type: ApplicationFiled: May 29, 2013Publication date: August 6, 2015Applicant: Sloan Kettering Institute for Cancer ResearchInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
-
Publication number: 20140112932Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: ApplicationFiled: August 23, 2013Publication date: April 24, 2014Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
-
Patent number: 8562993Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: GrantFiled: May 6, 2008Date of Patent: October 22, 2013Assignees: Board of Regents the University of Texas System, Sloan Kettering Institute for Cancer ResearchInventors: Jimmy Andrew Rotolo, Richard Kolesnick, Renata Pasqualini, Wadih Arap
-
Publication number: 20100239572Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: ApplicationFiled: May 6, 2008Publication date: September 23, 2010Applicant: Sloan Kettering Institute for Cancer ResearchInventors: Jimmy Andrew Rotolo, Richard Kolesnick, Renata Pasqualini, Wadih Arap
